Distribution of immunoreactivity for Cystatin B and Cathepsin S in the brain of Progressive myoclonus epilepsy (EPM1) patients

被引：0
|
作者：
D'Amato, E
Haltia, M
Rinne, A
de la Chapelle, A
Lehesjoki, AE
机构：
[1] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland
[2] Folkhalsan Inst Genet, FIN-00280 Helsinki, Finland
[3] Univ Helsinki, Dept Pathol, Helsinki, Finland
[4] Univ Tromso, Dept Med Biol, N-9037 Tromso, Norway
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 1998年 / 6卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P4211
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [21] Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1)
    Danner, Nils
    Julkunen, Petro
    Khyuppenen, Jelena
    Hukkanen, Taina
    Kononen, Mervi
    Saisanen, Laura
    Koskenkorva, Paivi
    Vanninen, Ritva
    Lehesjoki, Anna-Elina
    Kalviainen, Reetta
    Mervaala, Esa
    EPILEPSY RESEARCH, 2009, 85 (01) : 81 - 88
  • [22] Abnormal Microglial Activation in the Cstb-/- Mouse, A Model for Progressive Myoclonus Epilepsy, EPM1
    Okuneva, Olesya
    Korber, Inken
    Li, Zhilin
    Tian, Li
    Joensuu, Tarja
    Kopra, Outi
    Lehesjoki, Anna-Elina
    GLIA, 2015, 63 (03) : 400 - 411
  • [23] Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients
    Tarja Joensuu
    Mervi Kuronen
    Kirsi Alakurtti
    Saara Tegelberg
    Paula Hakala
    Antti Aalto
    Laura Huopaniemi
    Nina Aula
    Roberto Michellucci
    Kai Eriksson
    Anna-Elina Lehesjoki
    European Journal of Human Genetics, 2007, 15 : 185 - 193
  • [24] Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients
    Joensuu, Tarja
    Kuronen, Mervi
    Alakurtti, Kirsi
    Tegelberg, Saara
    Hakala, Paula
    Aalto, Antti
    Huopaniemi, Laura
    Aula, Nina
    Michellucci, Roberto
    Eriksson, Kai
    Lehesjoki, Anna-Elina
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2007, 15 (02) : 185 - 193
  • [25] Limitations of the UMRS for the evaluation of progression of myoclonus in progressive myoclonus epilepsy type 1 (EPM1) in the prospective follow-up
    Hypponen, Jelena
    Silvennoinen, Katri
    Saisanen, Laura
    Rissanen, Saara
    Karjalainen, Pasi
    Mervaala, Esa
    Kalviainen, Reetta K.
    EPILEPSIA, 2021, 62 : 73 - 74
  • [26] BACTERIAL CLONE CONTIGS IN THE PROGRESSIVE MYOCLONUS EPILEPSY (EPM1) REGION OF HUMAN-CHROMOSOME-21
    MYERS, RM
    STONE, NE
    FAN, JB
    WILLOUR, V
    HU, A
    FAHAM, M
    WARRINGTON, JA
    LEHESJOKI, AE
    DELACHAPELLE, A
    COX, DR
    AMERICAN JOURNAL OF HUMAN GENETICS, 1995, 57 (04) : 1543 - 1543
  • [27] EARLY ACTIVATION OF MICROGLIA HAS A CENTRAL ROLE IN THE DISEASE PATHOGENESIS OF PROGRESSIVE MYOCLONUS EPILEPSY, EPM1
    Korber, I.
    Joensuu, T.
    Lehesjoki, A. -E.
    Kopra, O.
    GLIA, 2013, 61 : S76 - S76
  • [28] Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy
    Rinne, R
    Saukko, P
    Järvinen, M
    Lehesjoki, AE
    ANNALS OF MEDICINE, 2002, 34 (05) : 380 - 385
  • [29] Progressive myoclonus epilepsy EPM1: A model for genetically determined susceptibility to seizure-induced neurodegeneration
    Lehesjoki, A.
    EPILEPSIA, 2006, 47 : 261 - 262
  • [30] EARLY ACTIVATION OF MICROGLIA HAS A CENTRAL ROLE IN THE DISEASE PATHOGENESIS OF PROGRESSIVE MYOCLONUS EPILEPSY, EPM1
    Korber, I
    Joensuu, T.
    Lehesjoki, A. E.
    Kopra, O.
    GLIA, 2011, 59 : S76 - S76
12345